37 results on '"Jahreis, Angelika"'
Search Results
2. P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data
3. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
4. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
5. Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis
6. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
7. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria
8. Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population
9. Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)
10. Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
11. OP0245 PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC
12. The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
13. Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez
14. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis
15. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis
16. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis
17. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
18. Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data
19. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
20. Using Registries to Identify Adverse Events in Rheumatic Diseases
21. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate
22. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial
23. Integrated safety in tocilizumab clinical trials
24. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing
25. A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis
26. Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
27. Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
28. Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database
29. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial
30. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis
31. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
32. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
33. Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial
34. Local tolerabilty of Tisocalcitate ointment in humans
35. Safety of large area application of a novel vitamin D analogue (Tisocalcitate ointment) in healthy volunteers
36. Safety of large area application of a novel vitamin D analogue (Tisocalcitate ointment) in patients with chronic plaque type psoriasis
37. CD40L Blockade Prevents Autoimmune Diabetes by Induction of Bitypic NK/DC Regulatory Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.